KHRN.V - Khiron Life Sciences Corp.

TSXV - TSXV Delayed Price. Currency in CAD
2.2500
-0.0400 (-1.75%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close2.2900
Open2.2800
Bid2.2400 x 0
Ask2.2500 x 0
Day's Range2.1900 - 2.3000
52 Week Range0.8700 - 4.3500
Volume310,001
Avg. Volume844,489
Market Cap252.785M
Beta (3Y Monthly)3.98
PE Ratio (TTM)N/A
EPS (TTM)-0.4360
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
  • CNW Group18 hours ago

    Khiron President Chris Naprawa to Participate in Grit Capital Virtual Investor Conference

    TORONTO , June 25, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (KHRN.V), (KHRNF), (Frankfurt:A2JMZC), a cannabis company with core operations in Latin America, announces today that Company president Chris Naprawa will be presenting at the Grit Capital Virtual Investor Conference to be hosted on June 26, 2019 . Khiron has core operations in Latin America and is fully licensed in the country for the cultivation, production, domestic distribution, and international export of both THC (tetrahydrocannabinol) and CBD (cannabidiol) medical cannabis.

  • CNW Group4 days ago

    Grit Capital's Live-Stream Virtual Investor Conference June 26th

    Grit Capital's Live-Stream Virtual Investor Conference June 26th

  • CNW Group6 days ago

    Khiron Completes Acquisition of NettaGrowth International Advancing Multi-Country Operator Strategy

    TORONTO , June 19, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (KHRN.V), (KHRNF), (Frankfurt:A2JMZC), a cannabis company with core operations in Latin America, announces that it has completed the acquisition of NettaGrowth International Inc. ("NettaGrowth"), previously announced on January 25, 2019 and April 9, 2019 , and its wholly-owned subsidiary Dormul S.A. ("Dormul"), a Uruguayan company that has obtained the first licence to produce and export medical cannabis with THC for commercialization in Uruguay . As consideration for the acquisition of NettaGrowth, Khiron has issued 8,498,821 common shares to the shareholders of NettaGrowth at a deemed price of $1.61 per common share.

  • PR Newswire11 days ago

    Khiron Announces Changes to Leadership Team with Appointment of Wendy Kaufman as CFO

    TORONTO, June 14, 2019 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (KHRN.V), (KHRNF), (Frankfurt: A2JMZC), a cannabis company with core operations in Latin America, today announced the appointment of Wendy Kaufman as CFO, effective July 2, 2019. Ms. Kaufman, a Chartered Professional Accountant, brings over 20 years of international financial experience, having served most recently as CFO at Pasinex Resources Limited.  Ms. Kaufman has significant experience with Latin American operations, gained during her tenure as CFO at Primero Mining Corporation, and previously in her role as Vice President, Finance and Treasury at Inmet Mining Corporation, among other executive management positions.

  • CNW Group18 days ago

    Khiron Receives Regulatory Approval for Uruguay Acquisition

    TORONTO , June 7, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (KHRN.V), (KHRNF), (Frankfurt:A2JMZC), a medical cannabis company with core operations in Latin America reports that the Company's previously announced agreement for the acquisition (the "Acquisition") of NettaGrowth International Inc. ("NettaGrowth"), which at closing will own all of the outstanding shares of a Uruguayan company, Dormul S.A. ("Dormul"), is progressing as planned. On June 5, 2019 , the Company secured local regulatory approvals in Uruguay for the completion of the Acquisition.

  • Cronos Stock Is Lagging Other Marijuana Names
    InvestorPlace19 days ago

    Cronos Stock Is Lagging Other Marijuana Names

    After receiving the backing of Altria Group Inc (NYSE:MO), Canada-based cannabis producer Cronos Group (NASDAQ:CRON) looked like it was headed for significant growth, but it has not delivered. As a result, the performance of CRON stock has been disappointingSince the deal, CRON has not made meaningful strides in production, which is the name of the game in cannabis, nor has the company expanded notably overseas. Without even factoring in the valuation of CRON stock, I have serious concerns about the company.CRON just does not have strong enough fundamentals to propel Cronos stock meaningfully higher. The company continues to lag its competitors in production, R&D, and new markets.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Stocks to Buy That Could Be Takeover Targets Capacity WoesCronos' production capacity is comparable to the likes of Organigram and CannTrust Holdings (NYSE:CTST), but the market gives CRON stock a substantially larger valuation.However, it is not clear why that gap is justified, since CRON is a less efficient grower and seller than its two competitors.Cronos, Organigram, and CannTrust Holdings all have similar capacity now and similar estimated capacity next year. Looking at recent results, though, Cronos clearly grows cannabis less efficiently and sells it less effectively. Cronos sold just 1,111 kg of cannabis last year, while Organigram sold 4,248 kg and CannTrust sold over 3,000 kg.Cronos is falling behind tremendously. CRON Doesn't Have an Edge OverseasCRON's international push does not seem to be materially different or more successful than that of its peers. Most of its overseas partnerships are in very competitive areas. Other players have been expanding much more aggressively, and CRON has less ground cultivated overseas than the competition, which will be a hindrance to its growth and to CRON stock.In Australia, for example, Cronos is aiming for annual production capacity of 2,000 kg. But that is peanuts compared to what Solaris Nutraceuticals Pty Ltd is doing. Its greenhouse will produce around 100,000 kg per year of medical cannabis.In Latin America, CRON has a 50/50 joint venture with AGI, Colombia's leading agricultural services provider. However, there has been a big increase in the number of cultivators in the region. Again, just as an example. AGI's 207 acres of available land pales in comparison to competitors like Colombia's Pharmacielo, which has over 15 million square feet of land. That translates roughly to production capacity of over 5,000 kilograms.There's also Khiron, a Colombian grower that has been expanding its own cultivation area. Its total area is estimated to be capable of producing 100,000 kilograms of dry flower for extraction and processing into medical cannabis.You get the idea.Europe is even more crowded. Germany and Poland, where many American-listed Canadian companies have been active in M&A and expanding their footprints, are particularly competitive. The Bottom Line on CRON StockThe cannabis industry is a very attractive space to be in, but there are bound to be some duds. At the moment, Cronos Group stock is shaping up to be a good name to short. One caveat is that Cronos does has a decent cash balance.Overall, investors can always generate profits by reducing exposure to the laggards and doubling down on the leaders. Investors should be reducing their exposure to CRON stock.As of this writing, Luce Emerson did not hold a position in any of the aforementioned securities. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * The 4 FANG Stocks Won't Be Bitten By Regulation Threats * 10 Stocks to Buy That Could Be Takeover Targets * 4 Big Bank Stocks Rebounding Compare Brokers The post Cronos Stock Is Lagging Other Marijuana Names appeared first on InvestorPlace.

  • CNW Group19 days ago

    Cannabis Virtual Investor Conference Presentations Now Available for On-Demand Viewing

    Cannabis Virtual Investor Conference Presentations Now Available for On-Demand Viewing

  • Market Exclusive20 days ago

    Cannabis Stock News Daily Roundup June 5

    High Tide (CSE: HITI) (OTCQB: HITIF) (FRA: 2LY) has opened a new Smoker's Corner retail store in the Royal Chapelle Area of Edmonton in Edmonton, Alberta. The Royal Chapelle Store will be supplied from the company's vast catalog of more than 4,300 SKUs of smoking accessories and cannabis lifestyle products, including the full range of proprietary […]The post Cannabis Stock News Daily Roundup June 5 appeared first on Market Exclusive.

  • Market Exclusive21 days ago

    Khiron Announces Completion Of Ibague Colombia Facility

    Khiron Life Sciences Corp (OTCMKTS:KHRNF) has announced the completion of construction and the start of operations for growing, extraction and processing in the Ibague Colombia facility. Progress has been made regarding commercial registration as well as the production of medical cannabis products that target over 6 million patients in Latin America . Milestones and progress […]The post Khiron Announces Completion Of Ibague Colombia Facility appeared first on Market Exclusive.

  • /R E P E A T -- Khiron Announces Completion of New Lab Facilities, With Initial Capacity of 3 Tonnes of Extract Per Year/
    PR Newswire22 days ago

    /R E P E A T -- Khiron Announces Completion of New Lab Facilities, With Initial Capacity of 3 Tonnes of Extract Per Year/

    TORONTO, June 2, 2019 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (KHRN.V), (KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, is pleased to announce the completion of construction and the initiation of operations in its cultivation, extraction, and analysis facilities in Ibague, Colombia, where significant progress has been made towards the commercial registration and production of medical cannabis products targeting 6 million potential patients across the country. Khiron currently owns and operates one of the most sophisticated medical cannabis cultivation and processing facilities in Latin America.

  • Khiron Announces Completion of New Lab Facilities, With Initial Capacity of 3 Tonnes of Extract Per Year
    CNW Group23 days ago

    Khiron Announces Completion of New Lab Facilities, With Initial Capacity of 3 Tonnes of Extract Per Year

    TORONTO , June 2, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (KHRN.V), (KHRNF), (Frankfurt:A2JMZC), a vertically integrated cannabis leader with core operations in Latin America , is pleased to announce the completion of construction and the initiation of operations in its cultivation, extraction, and analysis facilities in Ibague, Colombia , where significant progress has been made towards the commercial registration and production of medical cannabis products targeting 6 million potential patients across the country. Khiron currently owns and operates one of the most sophisticated medical cannabis cultivation and processing facilities in Latin America .

  • Market Exclusive25 days ago

    Khiron Life Sciences Added to ETFMG Alternative Harvest ETF

    Khiron Life Sciences (TSXV: KHRN) (OTCQB: KHRNF), a cannabis company with core operations in Latin America, said that it has been added the MJ ETFMG Alternative Harvest ETF (NYSE: MJ), a fund with approximately US$1.22 billion in assets currently under management. The company calls it an important development as it advances its strategy as a […]The post Khiron Life Sciences Added to ETFMG Alternative Harvest ETF appeared first on Market Exclusive.

  • CNW Group25 days ago

    Live Investor Conference & Webinar: Cannabis Industry Companies Present June 4th

    Live Investor Conference & Webinar: Cannabis Industry Companies Present June 4th

  • CNW Group25 days ago

    Khiron Life Sciences Reports First Quarter Fiscal 2019 Financial Results

    Khiron Life Sciences Reports First Quarter Fiscal 2019 Financial Results

  • PR Newswire26 days ago

    Khiron Life Sciences to Webcast Live on June 4th at VirtualInvestorConferences.com

    Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on VirtualInvestorConferences.com TORONTO , May 30, 2019 /PRNewswire/ ...

  • CNW Group27 days ago

    Khiron Announces Addition to $1.2B MJ ETFMG Alternative Harvest ETF

    TORONTO , May 29, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN, OTCQB:KHRNF), a cannabis company with core operations in Latin America is pleased to announce today its addition to the MJ ETFMG Alternative Harvest ETF (MJ) (the "Fund"), a fund with approximately US$1.22 billion in assets currently under management. This represents an important development for the Company as it advances its strategy as a Latin American cannabis company with global growth. The Fund tracks the Prime Alternative Harvest Index, designed to measure the performance of companies within the cannabis ecosystem benefiting from global medicinal and recreational cannabis legalization.